This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseLondon AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Surveillance

Understanding evolving resistance patterns is a key element in the quest to limit the rise of AMR.1

Antimicrobial Testing Leadership and Surveillance (ATLAS)

In 2017, Pfizer combined two global resistance surveillance programmes and launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website. It's one of the largest AMR surveillance programs in the world and has open access to healthcare workers, researchers and the global health community supporting easy access to critical resistance information. The system closely monitors global, regional and local resistance trends, allowing tracking of resistance and the main features include antimicrobial susceptibility geographic heat maps. ATLAS contains 15 years of continuous bacterial surveillance data, with more than 800 sites from over 75 countries. The data is updated every 6-8 months. ATLAS also contains 9 years of continuous fungal surveillance data, with more than 138 sites across over 40 countries.2

Pfizer and Wellcome Launch Surveillance Programme to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa3

Pfizer and Wellcome have recently announced the launch of a multi-year, public-private research collaboration with the governments of Ghana, Kenya, Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance (AMR) on patients living in low and middle-income countries.

This first-of-its kind partnership – known as Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR) - will provide governments and health authorities with comprehensive data in four sub-Saharan African countries where there is a high burden of infectious diseases, insufficient data and lack of capacity to implement critically needed infection prevention and control programmes.

BSAC Resistance Surveillance Project

Specifically in the UK, Pfizer supported the BSAC Resistance Surveillance Project, which was a well-established program designed to provide long-term surveillance of antimicrobial resistance. Data is available for the last 20 years for an extensive list of bacterial pathogens.4

Access to Medicine Foundation: AMR Benchmark Report

Our surveillance efforts were recognised by the 2020 AMR Benchmark report. Pfizer were recognised as the first company to share raw data on resistance collected via our open-access ATLAS surveillance program.5

Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access resourcesLoading
Pfizer's ATLAS Website

Sign up or login to Pfizer's ATLAS website

Sign in here Loading
See how Pfizer's work in Stewardship & Surveillance ranked in the recent AMR Benchmark report  AMR Benchmark reportLoading

Prescribing Information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)
Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for solution for infusion

​​​Cresemba® (isavuconazole)
Great Britain
Cresemba® (isavuconazole) 100mg hard capsules
Cresemba® (isavuconazole) 200mg powder for concentrate for solution for infusion 
Northern Ireland
Cresemba® (isavuconazonium sulfate) 200mg powder for concentrate for solution for infusion and Cresemba 100mg hard capsules

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo® (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo® (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion

References

Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last Accessed July 2020]​Pfizer. Antimicrobial Testing Leadership and Surveillance. Available at: https://atlas-surveillance.com [Last Accessed July 2020]​Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa. Available at:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-wellcome-launch-surveillance-program-combat [Last Accessed November 2023]​The British Society for Antimicrobial Chemotherapy. Resistance Surveillance project. Available at:https://bsac.org.uk/resistance-surveillance/#:~:text=The%20BSAC%20Antimicrobial%20Resistance%20Surveillance,and%20lower%20respiratory%20tract%20infections. [Last Accessed November 2023]Access to Medicine Foundation. Antimicrobial resistance benchmark 2020. Available at: https://accesstomedicinefoundation.org/resource/2020-antimicrobial-resistance benchmark#:~:text=The%202020%20Antimicrobial%20Resistance%20Benchmark,for%20appropriate%20access%20to%20antibiotics. [Last accessed November 2023].​
PP-UNP-GBR-7491. November 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​